Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000722915 | Prostate | Tumor | integrin-mediated signaling pathway | 40/3246 | 107/18723 | 5.96e-07 | 1.26e-05 | 40 |
GO:004358815 | Prostate | Tumor | skin development | 74/3246 | 263/18723 | 8.28e-06 | 1.22e-04 | 74 |
GO:000756514 | Prostate | Tumor | female pregnancy | 55/3246 | 193/18723 | 7.79e-05 | 8.11e-04 | 55 |
GO:004470613 | Prostate | Tumor | multi-multicellular organism process | 60/3246 | 220/18723 | 1.47e-04 | 1.34e-03 | 60 |
GO:000736912 | Prostate | Tumor | gastrulation | 52/3246 | 185/18723 | 1.76e-04 | 1.55e-03 | 52 |
GO:000756614 | Prostate | Tumor | embryo implantation | 20/3246 | 53/18723 | 3.27e-04 | 2.62e-03 | 20 |
GO:000170411 | Prostate | Tumor | formation of primary germ layer | 36/3246 | 121/18723 | 5.22e-04 | 3.82e-03 | 36 |
GO:003362712 | Prostate | Tumor | cell adhesion mediated by integrin | 24/3246 | 72/18723 | 7.41e-04 | 5.13e-03 | 24 |
GO:004206312 | Prostate | Tumor | gliogenesis | 73/3246 | 301/18723 | 1.35e-03 | 8.46e-03 | 73 |
GO:00100014 | Prostate | Tumor | glial cell differentiation | 55/3246 | 225/18723 | 4.13e-03 | 2.08e-02 | 55 |
GO:006145011 | Prostate | Tumor | trophoblast cell migration | 8/3246 | 17/18723 | 4.45e-03 | 2.20e-02 | 8 |
GO:00140371 | Prostate | Tumor | Schwann cell differentiation | 14/3246 | 40/18723 | 5.52e-03 | 2.61e-02 | 14 |
GO:004358912 | Prostate | Tumor | skin morphogenesis | 6/3246 | 11/18723 | 5.63e-03 | 2.63e-02 | 6 |
GO:00425522 | Prostate | Tumor | myelination | 34/3246 | 134/18723 | 1.19e-02 | 4.85e-02 | 34 |
GO:00435889 | Skin | AK | skin development | 67/1910 | 263/18723 | 9.02e-13 | 2.14e-10 | 67 |
GO:015011520 | Skin | AK | cell-substrate junction organization | 34/1910 | 101/18723 | 1.38e-10 | 2.05e-08 | 34 |
GO:000722910 | Skin | AK | integrin-mediated signaling pathway | 35/1910 | 107/18723 | 1.84e-10 | 2.59e-08 | 35 |
GO:003432919 | Skin | AK | cell junction assembly | 86/1910 | 420/18723 | 1.95e-10 | 2.68e-08 | 86 |
GO:000704419 | Skin | AK | cell-substrate junction assembly | 32/1910 | 95/18723 | 4.71e-10 | 5.26e-08 | 32 |
GO:003158920 | Skin | AK | cell-substrate adhesion | 74/1910 | 363/18723 | 4.40e-09 | 3.30e-07 | 74 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0451014 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa045124 | Cervix | HSIL_HPV | ECM-receptor interaction | 12/459 | 89/8465 | 2.95e-03 | 1.88e-02 | 1.52e-02 | 12 |
hsa0451023 | Cervix | HSIL_HPV | Focal adhesion | 21/459 | 203/8465 | 3.24e-03 | 2.02e-02 | 1.63e-02 | 21 |
hsa054127 | Cervix | HSIL_HPV | Arrhythmogenic right ventricular cardiomyopathy | 10/459 | 77/8465 | 8.34e-03 | 4.70e-02 | 3.80e-02 | 10 |
hsa0451211 | Cervix | HSIL_HPV | ECM-receptor interaction | 12/459 | 89/8465 | 2.95e-03 | 1.88e-02 | 1.52e-02 | 12 |
hsa0451033 | Cervix | HSIL_HPV | Focal adhesion | 21/459 | 203/8465 | 3.24e-03 | 2.02e-02 | 1.63e-02 | 21 |
hsa0541212 | Cervix | HSIL_HPV | Arrhythmogenic right ventricular cardiomyopathy | 10/459 | 77/8465 | 8.34e-03 | 4.70e-02 | 3.80e-02 | 10 |
hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa04510 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
hsa048101 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa045101 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
hsa048102 | Colorectum | SER | Regulation of actin cytoskeleton | 60/1580 | 229/8465 | 2.74e-03 | 2.02e-02 | 1.47e-02 | 60 |
hsa048103 | Colorectum | SER | Regulation of actin cytoskeleton | 60/1580 | 229/8465 | 2.74e-03 | 2.02e-02 | 1.47e-02 | 60 |
hsa048104 | Colorectum | MSS | Regulation of actin cytoskeleton | 68/1875 | 229/8465 | 4.27e-03 | 1.86e-02 | 1.14e-02 | 68 |
hsa048105 | Colorectum | MSS | Regulation of actin cytoskeleton | 68/1875 | 229/8465 | 4.27e-03 | 1.86e-02 | 1.14e-02 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ITGB4 | SNV | Missense_Mutation | rs756270166 | c.5071C>T | p.Arg1691Trp | p.R1691W | P16144 | protein_coding | tolerated(0.17) | possibly_damaging(0.697) | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
ITGB4 | SNV | Missense_Mutation | novel | c.1447N>C | p.Glu483Gln | p.E483Q | P16144 | protein_coding | tolerated(0.15) | possibly_damaging(0.706) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
ITGB4 | SNV | Missense_Mutation | | c.2795T>A | p.Met932Lys | p.M932K | P16144 | protein_coding | deleterious(0) | possibly_damaging(0.48) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ITGB4 | SNV | Missense_Mutation | | c.2795N>G | p.Met932Arg | p.M932R | P16144 | protein_coding | deleterious(0) | possibly_damaging(0.68) | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ITGB4 | SNV | Missense_Mutation | novel | c.2522N>A | p.Ala841Asp | p.A841D | P16144 | protein_coding | tolerated(0.66) | benign(0) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ITGB4 | SNV | Missense_Mutation | | c.2590N>G | p.Leu864Val | p.L864V | P16144 | protein_coding | tolerated(0.66) | benign(0.003) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
ITGB4 | SNV | Missense_Mutation | rs201487753 | c.3230G>A | p.Arg1077His | p.R1077H | P16144 | protein_coding | deleterious(0.01) | probably_damaging(0.952) | TCGA-BH-A0AU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ITGB4 | SNV | Missense_Mutation | novel | c.1148N>T | p.Thr383Ile | p.T383I | P16144 | protein_coding | tolerated(0.14) | possibly_damaging(0.797) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ITGB4 | SNV | Missense_Mutation | novel | c.168N>A | p.Phe56Leu | p.F56L | P16144 | protein_coding | deleterious(0.01) | probably_damaging(0.978) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
ITGB4 | SNV | Missense_Mutation | | c.4019G>A | p.Gly1340Glu | p.G1340E | P16144 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-E2-A1AZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |